McAlister Renee K, Talbott Mahsa S, Reddy Nishitha M
1 Department of Pharmacy Services, Vanderbilt University Medical Center, Nashville, USA.
2 Department of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, USA.
J Oncol Pharm Pract. 2019 Apr;25(3):706-709. doi: 10.1177/1078155217750463. Epub 2018 Jan 15.
Autoimmune hemolytic anemia occurs due to an interaction of IgG antibodies with protein antigens expressed on red blood corpuscles. Glucocorticoids are the mainstay of treatment for autoimmune hemolytic anemia. For patients not responding to initial therapy, other agents such as rituximab, immunosuppressive therapy, or splenectomy are considered. When refractory to these treatment options, alemtuzumab is an alternative agent. However, long-term outcomes of patients supporting its use are lacking. We present three patients with refractory autoimmune hemolytic anemia treated with alemtuzumab.
自身免疫性溶血性贫血是由于IgG抗体与红细胞上表达的蛋白质抗原相互作用所致。糖皮质激素是自身免疫性溶血性贫血治疗的主要药物。对于初始治疗无反应的患者，可考虑使用其他药物，如利妥昔单抗、免疫抑制治疗或脾切除术。当对这些治疗方案无效时，阿仑单抗是一种替代药物。然而，目前缺乏支持其使用的患者长期预后数据。我们报告了3例接受阿仑单抗治疗的难治性自身免疫性溶血性贫血患者。
